Novartis Facebook Share widget provokes DDMAC letter

Share this article:

A Facebook Share widget found on Novartis' Tasigna (nilotinib) website provoked a DDMAC untitled letter, the fourth DDMAC communiqué Novartis has received this year.

In a rare bit of footnoted exposition, letter writer Karen Rulli, DDMAC's acting group leader, demonstrated her knowledge of Facebook Share – a tool used by Facebook members to share content across profiles – noting that with “two clicks, visitors to a website can share any page of that website through Facebook by generating a link to the page, along with a thumbnail image and brief description…that will appear on the users' profiles and, depending on privacy settings, in the home page stream of all of the users' [Facebook] friends.”

The problem with Novartis' Tasigna share widget, according to the letter, was that it presents efficacy claims for Tasigna, but “fails to communicate any risk information.” The widget also “inadequately communicates Tasgina's indication and implies superiority over other products,” the letter said (screenshot of the website here).   

Several pages from the physician and consumer portions of the Tasigna website generate unlawful risk omission and a broadening of indication via Facebook Share (and a Share This tool, for use outside of Facebook), according to the letter. Additionally, shared content from one of the consumer-directed web pages calls Tasigna a “next generation” treatment, which “misleadingly suggests superiority over other tyrosine kinase inhibitors approved for use in the treatment of Ph+ CML,” a claim not supported by clinical data, the letter said. “DDMAC has previously provided written advisory comments to Novartis about the misleading implications of the phrase 'next generation' when referring to Tasigna," the letter admonished, citing advisory letters dated August 14, 2008, and January 25, 2010.

Novartis also failed to submit the shared content to FDA for review, although it did submit the Tasigna website itself, according to the letter.

Separately, Novartis received another Untitled Letter dated July 29 that took issue with a brochure for Exforge (amlodipine and valsartan), a high blood pressure treatment. The brochure overstated Exforge's efficacy, made unsubstantiated superiority claims, and omitted risks. AstraZeneca also got served with an Untitled Letter dated July 29, over a leave behind for its antipsychotic Seroquel XR, which overstated efficacy and omitted material facts and risks.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...